Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa controlled human malaria infection study of ChAd63 PvDBP and MVA PvDBP in healthy UK adults
2019-000643-27Phase 2Unknown
- Sponsor
- University of Oxford
- Start
- Nov 2019
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of ChAd63 PvDBP and MVA PvDBP in vivax malaria (2 arms), sponsored by University of Oxford. Primary endpoint: Parasite multiplication rate. Status: unknown.
02
Drugs
ChAd63 PvDBPMVA PvDBP
03
Conditions
vivax malaria
Beyond the preview
Go deeper on 2019-000643-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000643-27.